Changes in the mucus barrier of the rat during 5-fluorouracil-induced gastrointestinal mucositis

Scandinavian Journal of Gastroenterology

Volumn 43, Issue 1, 2008, Pages 59-65

  Saegusa, Yoichi ^a   Ichikawa, Takafumi ^a   Iwai, Tomohisa ^a   Goso, Yukinobu ^a   Okayasu, Isao ^a   Ikezawa, Tomoaki ^a   Shikama, Nobuaki ^a   Saigenji, Katsunori ^a   Ishihara, Kazuhiko ^a  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

5 fluorouracil; Chemotherapy; Jejunum; Mucin; Mucus cells; Preventive therapy

Indexed keywords

CYCLINE; FLUOROURACIL; MONOCLONAL ANTIBODY; MUCIN; PROTEIN ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIGESTIVE SYSTEM INFLAMMATION; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; IMMUNOHISTOCHEMISTRY; JEJUNUM; MALE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; FLUOROURACIL; GASTROINTESTINAL DISEASES; IMMUNOHISTOCHEMISTRY; JEJUNUM; MALE; MUCINS; MUCOSITIS; MUCUS; RATS; RATS, WISTAR;

EID: 37549072675     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.1080/00365520701579662     Document Type: Article

References (30)

1. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003;98:1531-9.
2. Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols. Cancer 1978;42:1747-59.
3. Rubenstein EB, Peterson DE, Schubert M, Keefe D, McGuire D, Epstein J, et al. Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 2004;100(Suppl 9): 2026-46.
4. Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Misoprostol and omeprazole in the prevention of chemotherapy-induced acute gastroduodenal mucosal injury. Cancer 1996;78:1447-82.
5. Sartori S, Trevisani L, Nielsen I, Tassinari D, Panzini I, Abbasciano V. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury. J Clin Oncol 2000;18:463-7.
6. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004;100:1995-25.
7. Grem JL. Fluorinated pyrimidines. In: Chabner B, Collins J, editors. Cancer chemotherapy: principles and practice. Philadelphia: Lippincott; 1990. p 180.
8. Shirasaka T, Taguti T. Timeline from discovery of 5-FU to development of an oral anticancer agent S-1 and its drug concept. Jpn J Cancer Chemother 2006;33:4-18 (in Japanese).
9. Korenaga D, Honda M, Yasuda M, Inutsuka S, Nozoe T, Tashiro H. Increased intestinal permeability correlates with gastrointestinal toxicity among formulations of the fluorouracil analogue tegafur in rats. Eur Surg Res 2002;58:351-6.
10. Pritchard DM, Potten CS, Hickman JA. The relationships between p53-dependent apoptosis, inhibition of proliferation, and 5-fluorouracil-induced histopathology in murine intestinal epithelia. Cancer Res 1998;58:5453-65.
11. Pritchard DM, Watson AJ, Potten CS, Jackman AL, Hickman JA. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci USA 1997;94:1795-9.
12. Tanaka A, Koji T. Prophylactic effect of L-glutamine against intestinal derangement induced 5-fluorouracil or indomethacin in rats. Jpn Pharmacol Ther 2002;30:455-62.
13. Azuumi Y, Ohara S, Ishihara K, Okabe H, Hotta K. Correlation of quantitative change of gastric mucosal glycoproteins with aspirin-induced gastric damage in rats. Gut 1980;21:533-7.
14. Ikezawa T, Ichikawa T, Adachi K, Sugano S, Ojima T, Nakamura Y, et al. Analysis of mucin composition in gastric juices of chronic rheumatic patients with upper gastrointestinal damage. Biomed Res 2005;26:147-51.
15. KojimaY Ishihara K, Komuro Y, Saigenji K, Hotta K. Effects of the M1 muscarinic receptor antagonist pirenzepine on gastric mucus glycoprotein in rats with or without ethanol-induced gastric damage. Scand J Gastroenterol 1992;27:764-8.
16. Ikezawa T, Goso Y, Ichikawa T, Hayashida H, Nakamura T, Kurihara M, et al. Immunohistochemical localization in rat gastrointestinal tract of a sialomucin species recognized by HCM31, a new anti-mucin monoclonal antibody. Biochem Res 2002;23:63-8.
17. Ishihara K, Kurihara M, Goso Y, Ota H, Katsuyama T, Hotta K. Establishment of monoclonal antibodies against carbohydrate moiety of gastric mucins distributed in the different sites and layers of rat gastric mucosa. Glycoconjugate J 1996;13:857-64.
18. Tsubokawa D, Goso Y, Sawaguchi A, Kurihara M, Ichikawa T, Suganuma T, et al. An anti-mucin monoclonal antibody, PGM34, against 6-sulfated blood-group H type 2 antigen on the carbohydrate moiety of mucin. FEBS J 2007;274: 1833-48.
19. Ota H, Katsuyama T. Alternating laminated array of two types of mucin in the human gastric surface mucous layer. Histochem J 1992;24:86-92.
20. Goso Y, Endo M, Kurihara M, Ishihara K. Characterization of oligosaccharide epitope recognized by anti-mucin monoclonal antibody, RGM21, using neogrycoconjugate technology. Glycoconjugate J 2005;22:347 [abstract].
21. Ikezawa T, Goso Y, Ichikawa T, Hayashida H, Kurihara M, Ishihara K, et al. Appearance of specific mucins recognized by monoclonal antibodies in rat gastric mucosa healing from HCL-induced gastric mucosal damage. J Gastroenterol 2004;39:113-9.
22. Goto T, Tomozawa N, Kobayashi E, Fujinuma A. A comparative pharmacology study between the intracolonic and oral routes of 5-FU administration in a colon cancer-bearing Yosida sarcoma rat model. J Pharmacol Sci 2004;95:163-73.
23. Ichikawa T, Ishihara K, Saigenji K, Hotta K. Effects of acid-inhibitory antiulcer drugs on mucin biosynthesis in the rat stomach. Eur J Pharmacol 1994;251:107-11.
24. Sheahan DG, Jervis HR. Comparative histochemistry of gastrointestinal mucosubstances. Am J Anat 1976;146: 103-31.
25. Kawakubo M, Ito Y, Okimura Y, Kobayashi M, Sakura K, Kasama S, et al. Natural antibiotic function of human gastric mucin against Helicobactor pylori infection. Science 2004; 305:1003-6.
26. Huang FS, Kemp CJ, Williams JL, Erwin CR, Warner BW. Role of epidermal growth factor and its receptor in chemotherapy-induced intestinal injury. Am J Physiol Gastrointest Liver Physiol 2002;282:432-42.
27. Kralovanszky J, Prajda N, Kerpel-Fronius S, Bagriji T, Kiss E, Peters GJ. Biochemical consequences of 5-fluorouracil gastrointestional toxicity in rats; effect of high-dose uridine. Cancer Chemother Pharmacol 1993;32:243-8.
28. Inomata A, Horii I, Suzuki K. 5-Fluorouracil-induced intestinal toxicity: what determines the severity of damage to murine intestinal crypt epithelia. Toxicol Lett 2002;133: 231-40.
29. Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metast Rev 1992;11:179-95.
30. Hattori T, Arizono N. Cell kinetics and secretion of mucus in the gastrointestinal mucosa, and their diurnal rhythm. J Clin Gastroenterol 1988;10:1-6.